Discloure Notice

Disclosure Notice

Stockholm, February 11, 2004

Investor's share of the voting rights and share capital in AstraZeneca
has changed through the divestment of 21,200,000 shares.

After the sale, Investor's holding in AstraZeneca now amounts to
63,465,810 shares corresponding to 3.75 percent of the voting rights and
share capital. On December 31, 2003, Investor's holding in AstraZeneca
amounted to 5.0 percent of the votes and capital.

In a statement, Investor President and CEO Marcus Wallenberg said:
"We have decided to reduce our leverage and strengthen our financial
flexibility. We continue to believe strongly in AstraZeneca and the
company is still our largest holding."

INVESTOR AB

For further information:
Fredrik Lindgren, Vice President, Corporate Communications:
+46 8 614 20 31, +46 735 24 20 31